These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
120 related items for PubMed ID: 26021284
1. Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma? Mocikova H, Pytlik R, Stepankova P, Michalka J, Markova J, Koren J, Buresova L, Raida L, Kral Z. Acta Haematol; 2015; 134(3):187-92. PubMed ID: 26021284 [Abstract] [Full Text] [Related]
2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ. Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [Abstract] [Full Text] [Related]
6. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, Bartlett NL. J Clin Oncol; 2014 Mar 20; 32(9):912-8. PubMed ID: 24516013 [Abstract] [Full Text] [Related]
7. Nodular lymphocyte predominant Hodgkin's lymphoma. Siddiqui N, Al-Diab AI. Saudi Med J; 2005 Feb 20; 26(2):241-5. PubMed ID: 15770298 [Abstract] [Full Text] [Related]
11. Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma. Galán L, Sánchez AC, Cantos B, Provencio M. Clin Transl Oncol; 2010 May 20; 12(5):384-6. PubMed ID: 20466624 [Abstract] [Full Text] [Related]
12. Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience. Gemici A, Aydogdu I, Terzi H, Sencan M, Aslan A, Kaya AH, Dal MS, Akay MO, Dogu MH, Ayyildiz O, Sahin F, Cagliyan GA, Yilmaz M, Gokgoz Z, Bilen Y, Demir C, Sevindik OG, Korkmaz S, Eser B, Altuntas F, ThREG, Turkish hematology Research and Education Group. Hematol Oncol; 2018 Feb 20; 36(1):116-120. PubMed ID: 28707314 [Abstract] [Full Text] [Related]
14. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. Eichenauer DA, Plütschow A, Fuchs M, von Tresckow B, Böll B, Behringer K, Diehl V, Eich HT, Borchmann P, Engert A. J Clin Oncol; 2015 Sep 10; 33(26):2857-62. PubMed ID: 26240235 [Abstract] [Full Text] [Related]
16. Long-term follow-up of 2 patients treated with 90 Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma. Golstein SC, Muylle K, Vercruyssen M, Spilleboudt C, de Wind A, Bron D. Eur J Haematol; 2018 Sep 10; 101(3):415-417. PubMed ID: 29719928 [Abstract] [Full Text] [Related]
17. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, Reman O, Lepage E, Fermé C. Cancer; 1996 Sep 15; 78(6):1293-9. PubMed ID: 8826953 [Abstract] [Full Text] [Related]